08:00 , Nov 24, 2014 |  BC Week In Review  |  Company News

Nicox, OptiMed deal

Nicox granted OptiMed exclusive rights in Australia and New Zealand to distribute AdenoPlus and Xailin. AdenoPlus is an in vitro diagnostic that aids in the differential diagnosis of acute conjunctivitis, and Xailin a multidose carbomer...
08:00 , Nov 10, 2014 |  BC Week In Review  |  Company News

Doliage, Nicox deal

Nicox acquired French ophthalmic play Doliage for EUR5 million ($6.2 million) in newly issued Nicox shares. Nicox said the acquisition is part of its strategy to develop an ophthalmic commercial infrastructure in the five major...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Company News

Nicox, Nitto Medic deal

Nicox granted Nitto Medic exclusive, Japanese rights to distribute AdenoPlus, an in vitro diagnostic that aids in the differential diagnosis of acute conjunctivitis. Nicox will receive €500,000 ($656,650) up front, and Nitto Medic will purchase...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Company News

Nicox, Rapid Pathogen Screening deal

Nicox said it has paid a total of $3 million to RPS in license and option fees and has contributed to half of the development costs of RPS-AP and RPS-OH. Under the amended agreement, Nicox...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Company News

Eupharmed, Nicox deal

Nicox acquired ophthalmic company Eupharmed for €3.5 million ($4.7 million) in newly issued Nicox shares. The number of shares will be based on Nicox's average closing price during the 90-day period preceding the completion of...
07:00 , Oct 29, 2012 |  BC Week In Review  |  Company News

Nicox sales and marketing update

NicOx launched AdenoPlus in the U.S. to diagnose acute conjunctivitis. The point-of-care diagnostic that tests patients for adenoviral conjunctivitis using a tear sample has 510(k) clearance and a CLIA waiver in the U.S. The product...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Company News

Nicox, Rapid Pathogen Screening deal

Rapid granted NicOx exclusive, worldwide rights to commercialize several ophthalmic diagnostics.The deal includes AdenoPlus adenoviral conjunctivitis diagnostic and two diagnostics in development - RPS-AP for detecting adenoviral and allergic conjunctivitis and RPS-OH to diagnose ocular...